Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Editorial

Progress in the Development of Agonists, Antagonists and Allosteric Modulators of Adenosine Receptors

Author(s): Pran Kishore Deb

Volume 25 , Issue 25 , 2019

Page: [2695 - 2696] Pages: 2

DOI: 10.2174/138161282525190916100149

[1]
Fredholm BB, IJzerman AP, Jacobson KA, Klotz K-N, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001; 53: 527-52.
[2]
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol Rev 2011; 63(1): 1-34.
[3]
Borea PA, Varani K, Gessi S, Merighi S, Vincenzi F. The Adenosine Receptors. Springer 2018.
[4]
Merighi S, Gessi S, Borea PA. Adenosine Receptors: Structure, Distribution, and Signal Transduction. In: ed. The Adenosine Receptors. Springer 2018; pp. 33-57.
[5]
Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: the state of the art. Physiol Rev 2018; 98: 1591-625.
[6]
Borea PA, Gessi S, Merighi S, Varani K. Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects? Trends Pharmacol Sci 2016; 37: 419-34.
[7]
Gao Z-G, Tosh DK, Jain S, Yu J, Suresh RR, Jacobson KA. A1 Adenosine Receptor Agonists, Antagonists, and Allosteric Modulators. In: ed. The Adenosine Receptors Springer. 2018; 59-89.
[8]
Kiesman WF, Elzein E, Zablocki JA. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. In: ed. Adenosine receptors in health and disease Springer,. 2009; 25-58.
[9]
Elzein E, Zablocki J. A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 2008; 17: 1901-10.
[10]
Shaik K, Deb PK, Mailavaram RP, et al. 7-Amino-2-aryl/heteroaryl-5-oxo-5,8-dihydro[1,2,4]triazolo[1,5-a]pyridine-6-carbonitriles: Synthesis and Adenosine Receptor Binding Studies. Chem Biol Drug Des 2019; 94: 1568-73.
[11]
Chandrasekaran B, Deb PK, Kachler S, Akkinepalli RR, Mailavaram R, Klotz K-N. Synthesis and adenosine receptors binding studies of new fluorinated analogues of pyrido [2,3-d]pyrimidines and quinazolines. Med Chem Res 2018; 27: 756-67.
[12]
Varani K, Vincenzi F, Merighi S, Gessi S, Borea PA. Biochemical and pharmacological role of A1 adenosine receptors and their modulation as novel therapeutic strategy. In: ed. Protein Reviews Springer.. 2017; 193-232.
[13]
Romagnoli R, Baraldi PG, Moorman AR, Borea PA, Varani K. Current status of A1 adenosine receptor allosteric enhancers. Future Med Chem 2015; 7: 1247-59.
[14]
Kazemi MH, Raoofi MS, Hojjat-Farsangi M, et al. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. J Cell Physiol 2018; 233: 2032-57.
[15]
Pinna A. Adenosine A2A receptor antagonists in Parkinson’s disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs 2014; 28: 455-74.
[16]
Preti D, Baraldi PG, Moorman AR, Borea PA, Varani K. History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents. Med Res Rev 2015; 35: 790-848.
[17]
Kalla RV, Zablocki J. Progress in the discovery of selective, high affinity A2B adenosine receptor antagonists as clinical candidates. Puriner Sig 2009; 5: 21-9.
[18]
Sun Y, Huang P. Adenosine A2B receptor: from cell biology to human diseases. Front Chem 2016; 4: 37.
[19]
Wilson CN, Nadeem A, Spina D, Brown R, Page CP, Mustafa SJ. Adenosine receptors and asthma. In: ed. Adenosine Receptors in Health and Disease Springer. 2009; 329-62.
[20]
Jacobson KA, Tosh DK, Gao Z-G, et al. Medicinal Chemistry of the A3 Adenosine Receptor. In: ed. The Adenosine Receptors Springer. 2018; 169-98..
[21]
Brown R, Spina D, Page C. Adenosine receptors and asthma. Br J Pharmacol 2008; 153: S446-56.
[22]
Deb PK. Recent Updates in the Computer Aided Drug Design Strategies for the Discovery of Agonists and Antagonists of Adenosine Receptors. In: ed. Bentham Science 2019; 747-9.
[23]
Deb PK, Chandrasekaran B, Mailavaram R, Tekade RK, Jaber AMY. Molecular modeling approaches for the discovery of adenosine A2B receptor antagonists: current status and future perspectives. Drug Discov Today 2019; pii: S1359-6446(19): 30045-5.
[24]
Deb PK, Balakumar C, Rao AR, Roy PP, Roy K. QSAR of adenosine receptor antagonists: exploring physicochemical requirements for binding of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives with human adenosine A3 receptor subtype. Bioorg Med Chem Lett 2011; 21: 818-23.
[25]
Samanta PN, Kar S, Leszczynski J. Recent Advances of In-Silico Modeling of Potent Antagonists for the Adenosine Receptors. Curr Pharm Des 2019; 25: 750-73.
[26]
Agrawal N, Chandrasekaran B, Al-Aboudi A. Recent Advances in the In-silico Structure-based and Ligand-based Approaches for the Design and Discovery of Agonists and Antagonists of A2A Adenosine Receptor. Curr Pharm Des 2019; 25: 774-82.
[27]
Al-Shar’i NA, Al-Balas QA. Molecular Dynamics Simulations of Adenosine Receptors: Advances, Applications and Trends. Curr Pharm Des 2019; 25: 783-816.
[28]
Al-Qattan M, Mordi M. Molecular basis of modulating adenosine receptors activities. Curr Pharm Des 2019; 25: 817-31.
[29]
Deb PK, Al-Attraqchi O, Al-Qattan MN, Prasad MR, Tekade RK. Applications of Computers in Pharmaceutical Product Formulation. In: ed. Dosage Form Design Parameters Elsevier. 2018; 665-703.
[30]
Deb PK, Mailavaram R, Chandrasekaran B, et al. Synthesis, adenosine receptor binding and molecular modelling studies of novel thieno[2,3d]pyrimidine derivatives. Chem Biol Drug Des 2018; 91: 962-9.
[31]
Jaakola V-P, Griffith MT, Hanson MA, et al. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008; 322: 1211-7.
[32]
Glukhova A, Thal DM, Nguyen AT, et al. Structure of the adenosine A1 receptor reveals the basis for subtype selectivity. Cell 2017; 168: 867-77.
[33]
Cheng RK, Segala E, Robertson N, et al. Structures of human A1 and A2A adenosine receptors with xanthines reveal determinants of selectivity. Structure 2017; 25: 1275-85.
[34]
Deb PK, Deka S, Borah P, Abed SN, Klotz K-N. Medicinal chemistry and therapeutic potential of agonists, antagonists and allosteric modulators of A1 adenosine receptor: current status and perspectives. Curr Pharm Des 2019; 25(25): 2697-715.
[35]
Al-Attraqchi OHA, Attimarad M, Venugopala KN, Nair A, Al-Attraqchi NHA. Adenosine A2A receptor as a potential drug target - current status and future perspectives. Curr Pharm Des 2019; 25(25): 2716-40.
[36]
Chandrasekaran B, Samarneh S, Kassab G, Agrawal N. Therapeutic potentials of A2B adenosine receptor ligands: Current status and perspectives. Curr Pharm Des 2019; 25(25): 2741-71.
[37]
Mailavaram RP, Al-Attraqchi OHA, Kar S, Ghosh S. Current status in the design and development of agonists and antagonists of adenosine A3 receptor as potential therapeutic agents. Curr Pharm Des 2019; 25(25): 2772-87.

© 2022 Bentham Science Publishers | Privacy Policy